Zealand Pharma delivers strong clinical results during the first half of 2019 and accelerates commercial build-up in the U.S.
(WorldNews Denmark)

Company announcement - No. 25 / 2019 Zealand Pharma delivers strong clinical results during the first half of 2019 and accelerates commercial build-up in the U.S. Copenhagen, August 15, 2019- Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR No. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of next generation peptide medicines, today announced financial results for the first half of 2019. Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma, comments: "We continue to advance our research and clinical development programs, and are accelerating the first steps in building commercial operations in the U.S. Our...